Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (14638)	9/16/2000 8:47:16 PM
From: Cacaito	Read Replies (1) \| Respond to of 17367

1st to prove bpi worth there will not be a single child excess death as far as what we KNOW now, not what we wish. It is a moral imperative that in medical research scientists acts with proven FACTS, and the informed consent must present to the subject (or their surrogates, like the parents)what is the possible but uncertain, so they can make the desicion. Not a single child will be in excess jeopardy of death for missing bpi, and xoma could not even make the claim of less amputations except for a trend, this is still the range of possible but uncertain. A full trial with 900 to 3000 subjects will be neccesary to get this going, lets go xoma, bax show you are for the kids, bring the $100 M for the trial.